344 related articles for article (PubMed ID: 25866814)
1. Chemotherapy and chemoprevention by thiazolidinediones.
Fröhlich E; Wahl R
Biomed Res Int; 2015; 2015():845340. PubMed ID: 25866814
[TBL] [Abstract][Full Text] [Related]
2. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors.
Nemenoff RA
J Thorac Oncol; 2007 Nov; 2(11):989-92. PubMed ID: 17975488
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
Chana RS; Brunskill NJ
Am J Nephrol; 2006; 26(1):67-74. PubMed ID: 16508249
[TBL] [Abstract][Full Text] [Related]
6. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
Mughal A; Kumar D; Vikram A
Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
8. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
11. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B
Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
[TBL] [Abstract][Full Text] [Related]
12. The potential of antidiabetic thiazolidinediones for anticancer therapy.
Galli A; Mello T; Ceni E; Surrenti E; Surrenti C
Expert Opin Investig Drugs; 2006 Sep; 15(9):1039-49. PubMed ID: 16916271
[TBL] [Abstract][Full Text] [Related]
13. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.
Jarrar MH; Baranova A
J Cell Mol Med; 2007; 11(1):71-87. PubMed ID: 17367502
[TBL] [Abstract][Full Text] [Related]
14. [Anti-cancer action by PPARgamma ligand].
Okumura T
Nihon Rinsho; 2010 Feb; 68(2):267-72. PubMed ID: 20158095
[TBL] [Abstract][Full Text] [Related]
15. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture.
Fröhlich E; Machicao F; Wahl R
Endocr Relat Cancer; 2005 Jun; 12(2):291-303. PubMed ID: 15947104
[TBL] [Abstract][Full Text] [Related]
16. Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.
Kuntz S; Mazerbourg S; Boisbrun M; Cerella C; Diederich M; Grillier-Vuissoz I; Flament S
Biochem Pharmacol; 2014 Nov; 92(1):102-11. PubMed ID: 25083915
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
[TBL] [Abstract][Full Text] [Related]
18. A new dawn for the use of thiazolidinediones in cancer therapy.
Joshi H; Pal T; Ramaa CS
Expert Opin Investig Drugs; 2014 Apr; 23(4):501-10. PubMed ID: 24597633
[TBL] [Abstract][Full Text] [Related]
19. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
Demerjian M; Man MQ; Choi EH; Brown BE; Crumrine D; Chang S; Mauro T; Elias PM; Feingold KR
Exp Dermatol; 2006 Mar; 15(3):154-60. PubMed ID: 16480422
[TBL] [Abstract][Full Text] [Related]
20. PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells.
Koch A; Völzke A; Puff B; Blankenbach K; Meyer Zu Heringdorf D; Huwiler A; Pfeilschifter J
Biochim Biophys Acta; 2013 Nov; 1831(11):1634-43. PubMed ID: 23906789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]